PMID- 24868005
OWN - NLM
STAT- MEDLINE
DCOM- 20150910
LR  - 20181202
IS  - 1940-2465 (Electronic)
IS  - 1066-8969 (Linking)
VI  - 23
IP  - 1
DP  - 2015 Feb
TI  - Anaplastic lymphoma kinase-positive large B-cell lymphoma: description of a case 
      with an unexpected clinical outcome.
PG  - 78-83
LID - 10.1177/1066896914536223 [doi]
AB  - Anaplastic lymphoma kinase-positive (ALK-positive) large B-cell lymphoma is a 
      rare and aggressive variant of large B-cell lymphoma (LBCL), first reported by 
      Delsol et al in 1997, showing distinctive morphologic, immunophenotypic and 
      cytogenetic features. The latest 2008 World Health Organization Classification of 
      Tumours of Haematopoietic and Lymphoid tissues recognizes ALK-positive LBCL as a 
      separate entity. Here, we report a case of ALK-positive large B-cell lymphoma in 
      a 53-year-old man with diffuse abdominal and mediastinal lymph-nodes involvement. 
      According to the Ann Arbor staging system, the patient had a stage IIIB lymphoma. 
      The age-adjusted International Prognostic Index was 2 (stage III and elevated 
      lactate dehydrogenase), so the disease was considered high risk. The patient 
      underwent chemotherapy, radiotherapy, and an autologous stem cell 
      transplantation. The patient is alive and free of disease 35 months after 
      diagnosis.
CI  - (c) The Author(s) 2014.
FAU - Zanelli, Magda
AU  - Zanelli M
AD  - Anatomic Pathology Unit, IRCSS Santa Maria Nuova Hospital, Reggio Emilia, Italy.
FAU - Valli, Riccardo
AU  - Valli R
AD  - Anatomic Pathology Unit, IRCSS Santa Maria Nuova Hospital, Reggio Emilia, Italy.
FAU - Capodanno, Isabella
AU  - Capodanno I
AD  - Anatomic Pathology Unit, IRCSS Santa Maria Nuova Hospital, Reggio Emilia, Italy.
FAU - Ragazzi, Moira
AU  - Ragazzi M
AD  - Anatomic Pathology Unit, IRCSS Santa Maria Nuova Hospital, Reggio Emilia, Italy 
      moira.ragazzi@asmn.re.it.
FAU - Ascani, Stefano
AU  - Ascani S
AD  - Hematology Unit, IRCSS Santa Maria Nuova Hospital, Reggio Emilia, Italy.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20140526
PL  - United States
TA  - Int J Surg Pathol
JT  - International journal of surgical pathology
JID - 9314927
RN  - 04079A1RDZ (Cytarabine)
RN  - 5J49Q6B70F (Vincristine)
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
RN  - UM20QQM95Y (Ifosfamide)
RN  - YL5FZ2Y5U1 (Methotrexate)
RN  - ANAVACYM protocol
RN  - IVAC protocol
SB  - IM
MH  - Anaplastic Lymphoma Kinase
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Cyclophosphamide/therapeutic use
MH  - Cytarabine/therapeutic use
MH  - Doxorubicin/therapeutic use
MH  - Etoposide/therapeutic use
MH  - Humans
MH  - Ifosfamide/therapeutic use
MH  - Lymphoma, Large B-Cell, Diffuse/drug therapy/metabolism/*pathology
MH  - Male
MH  - Methotrexate/therapeutic use
MH  - Middle Aged
MH  - Receptor Protein-Tyrosine Kinases/*metabolism
MH  - Remission Induction
MH  - Treatment Outcome
MH  - Vincristine/therapeutic use
OTO - NOTNLM
OT  - ALK positivity
OT  - ALK-positive large B-cell lymphoma
OT  - anaplastic lymphoma kinase (ALK)
OT  - immunohistochemistry
OT  - large B-cell lymphoma
OT  - t(2; 17)
EDAT- 2014/05/29 06:00
MHDA- 2015/09/12 06:00
CRDT- 2014/05/29 06:00
PHST- 2014/05/29 06:00 [entrez]
PHST- 2014/05/29 06:00 [pubmed]
PHST- 2015/09/12 06:00 [medline]
AID - 1066896914536223 [pii]
AID - 10.1177/1066896914536223 [doi]
PST - ppublish
SO  - Int J Surg Pathol. 2015 Feb;23(1):78-83. doi: 10.1177/1066896914536223. Epub 2014 
      May 26.